Catalyst Wire Dossier Catalyst Wire Dossier

doravirine/tenofovir/lamivudine (MK-1439A)

doravirine/tenofovir/lamivudine · Merck Sharp & Dohme LLC
Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for doravirine/tenofovir/lamivudine (MK-1439A), covering 2019-12-26 to 2019-12-26. Get the full timeline:

Most recent: Clinical Trial Update: Safety and Efficacy of Doravirine, Tenofovir, Lamivudine (MK-1439A) in Participants Infected With Treatment-Naïve Human Immunodeficiency Virus (HIV) -1 With Transmitted Resistance (MK-1439A-030) [Phase 2]

See pricing